FGFR2 N550K

CI-VAR-00002919Explore in graph →NP_075259.4:p.Asn550LysNM_022970.3:c.1650T>AClinVar 376157 CIViC 545 rs121913476

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Endometrial Neoplasm1
FGFR2 N550K	PD173074	Predictive	D	Supports Sensitivity Response	3	accepted	EID1322 The endometrial cancer cell lines, AN3CA and MFE296, which carry the N550K FGFR2 mutation, were found to be sensitive to FGFR inhibition with PD174074 (10 to 40x more sensitive than cell lines with wi… (full text at CIViC) PMID 18757403 · Byron et al., 2008 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.